NT-proBNP as an Early Diagnostic Marker of Chronic Heart Failure

Abstract

NT-proBNP is a validated biomarker that reflects ventricular filling pressure and myocardial wall stress. It demonstrates high sensitivity for excluding heart failure (HF) in both acute and outpatient clinical settings and provides significant prognostic information. Randomized controlled trials and systematic reviews have demonstrated the benefits of targeted screening among high-risk groups (such as patients with diabetes, post-myocardial infarction, or chronic kidney disease) when combined with structured follow-up programs (echocardiography referral, therapy optimization). However, current evidence is insufficient to support population-wide screening of asymptomatic individuals. Major clinical guidelines (ESC 2021, AHA/ACC/HFSA 2022) recommend the use of natriuretic peptides for both diagnostic purposes and clinical triage